Contact Us  





Division of Medical Oncology
University of Colorado Denver
12801 E. 17th Avenue
Aurora, CO  80010
Ph:  (303) 724-3888
Fax:  (303  724-3889
info@deptofmed.edu


 



Ana Belen Oton, MD.
Assistant Professor
Cardiothoracic Malignancies
Denver Health Medical Center

Education: Medical School-University Central of Venezuela at Caracas. June 1998

University of Colorado Denver
School of Medicine, Division of Medical Oncology
Tel: (303) 436-6171
Fax: (303) 436-3801
e-mail: ana.oton@uchsc.edu


Bio
Dr. Oton joined the faculty of the University of Colorado Denver in July 2007.  She is fluent in English and Spanish.

Research
Dr. Oton is focused on clinical cancer research. Her major interest is in new drug development in lung cancer and thoracic malignancies. Dr. Oton will be the principal investigator on several therapeutic trials at Denver Health and the University of Colorado. She started her research career at the University of Pittsburgh with a focus in the differences in lung cancer survival between pre-menopausal and post-menopausal women.

 

FACULTY LIST

Lynn Bemis
Virginia Borges
Paul Bunn
David Calverley
Ross Camidge
Dan Chan
Gail Eckhardt
Anthony Elias
Thomas Flaig
Marileila Garcia
L. Michael Glode
Rene Gonzalez
Barb Helfrich
Fred Hirsch
Christopher Hogan
Antonio Jimeno
Madeleine Kane
Choon-Kee Lee
Stephen Leong
Wells Messersmith
Han Myint
Ana Oton
Peter Raich
William Robinson
Pepper Schedin
John Tentler
William Tse
Colin Weekes

Publications, etc.
Owonikoko T, Ragin C, Belani CP, Oton A, Gooding W, Taioli E, Ramalingam S Lung Cancer in Elderly Patients: An Analysis of the SEER Database, Accepted for publication in Journal of Clinical Oncology, August 2007

Feng R, Oton A, Mapara M, Anderson G, Belani C, Lentzsch S. The Histone Deacetylase Inhibitor, PXD101, potentiates bortezomib-induced and anti-multiple myeloma effect by Induction of Oxidative Stress and DNA Damage. Br J of Haematology November 2007, 139(3):385-397

Oton A, Hong W, Melhem M, George D, Foon K, Ghobrial IM. Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders, BCL2 as Poor Prognostic Marker. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I (supplement). June 2007, 25(18S): 8073

Oton A, Belani C, Siegfried J, Ramalingam S. Comparison of Survival for Lung Cancer between Premenopausal and Postmenopausal Women: An Analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. 2006 ASCO Annual Meeting, JCO.


PubMed articles

BACK TO TOP




Home  |  About  |  Faculty  |  Staff  |  Research  |  Clinical Trials  |  Fellowship 
Make a Donation  |  Employee Resources  |  Patient Information  |  Calendar
 
 
  Division of Medical Oncology
Copyright © 2008 University of Colorado Denver

Privacy Practices  
ds="14,39,391,97" href="../index.htm" />